Remarkable progress has been made in recent decades in engineering antibodies and
other protein therapeutics, including enhancements to existing functions as well as the …

The camelid single-domain antibody fragment, commonly referred to as a nanobody,
achieves the targeting power of conventional monoclonal antibodies (mAbs) at only a …

Designing effective monoclonal antibody (mAb) therapeutics faces a multi-parameter
optimization challenge known as “developability”, which reflects an antibody's ability to …

Antibodies are a popular and powerful class of therapeutic due to their ability to exhibit high
affinity and specificity to target proteins. However, the majority of antibody therapeutics are …

Motivation Nanobodies are a subclass of immunoglobulins, whose binding site consists of
only one peptide chain, bestowing favorable biophysical properties. Recently, the first …

We investigate the potential of patent data for improving the antibody humanness prediction
using a multi-stage, multi-loss training process. Humanness serves as a proxy for the …

Nanobodies can provide specific binding to divergent antigens, leading to many promising
therapeutic and detection applications in recent years. Traditional technologies of nanobody …

In-silico prediction of protein biophysical traits is often hindered by the limited availability of
experimental data and their heterogeneity. Training on limited data can lead to overfitting …

To be viable therapeutics, antibodies must be tolerated by the human immune system.
Rational approaches to reduce the risk of unwanted immunogenicity involve maximizing the …

The development of bispecific antibodies that bind at least two different targets relies on
bringing together multiple binding domains with different binding properties and biophysical …